ATE106729T1 - Verfahren und zusammensetzung zur behandlung und vorbeugung von virus-infektionen. - Google Patents

Verfahren und zusammensetzung zur behandlung und vorbeugung von virus-infektionen.

Info

Publication number
ATE106729T1
ATE106729T1 AT88302275T AT88302275T ATE106729T1 AT E106729 T1 ATE106729 T1 AT E106729T1 AT 88302275 T AT88302275 T AT 88302275T AT 88302275 T AT88302275 T AT 88302275T AT E106729 T1 ATE106729 T1 AT E106729T1
Authority
AT
Austria
Prior art keywords
treatment
prevention
composition
virus infections
steroids
Prior art date
Application number
AT88302275T
Other languages
English (en)
Inventor
Anthony Atkinson
Graham Lloyd
Peter Morgan Sutton
Original Assignee
Health Lab Service Board
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Health Lab Service Board filed Critical Health Lab Service Board
Application granted granted Critical
Publication of ATE106729T1 publication Critical patent/ATE106729T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
AT88302275T 1987-03-17 1988-03-16 Verfahren und zusammensetzung zur behandlung und vorbeugung von virus-infektionen. ATE106729T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB878706313A GB8706313D0 (en) 1987-03-17 1987-03-17 Treatment & prevention of viral infections

Publications (1)

Publication Number Publication Date
ATE106729T1 true ATE106729T1 (de) 1994-06-15

Family

ID=10614085

Family Applications (1)

Application Number Title Priority Date Filing Date
AT88302275T ATE106729T1 (de) 1987-03-17 1988-03-16 Verfahren und zusammensetzung zur behandlung und vorbeugung von virus-infektionen.

Country Status (10)

Country Link
US (1) US4957910A (de)
EP (1) EP0285285B1 (de)
JP (1) JPS63301823A (de)
AT (1) ATE106729T1 (de)
AU (1) AU619174B2 (de)
CA (1) CA1317224C (de)
DE (1) DE3889964T2 (de)
DK (1) DK143088A (de)
GB (1) GB8706313D0 (de)
ZA (1) ZA881856B (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO178843C (no) * 1988-07-11 1996-06-19 Sspl Sa Safe Sex Prod Licens Fremgangsmåte for fremstilling av et farmasöytisk preparat for å forhindre seksuelt overförbare sykdommer
EP0435926A1 (de) * 1988-09-20 1991-07-10 FISONS plc Gallensäuren zur behandlung von viralen infektionen
DK603988D0 (da) * 1988-10-28 1988-10-28 Klaus Bendtzen Farmaceutisk praeparat
US5079240A (en) * 1990-03-15 1992-01-07 The Regents Of The University Of California Synthetic conjugated bile acid and method of use thereof
US5206008A (en) * 1991-04-15 1993-04-27 Virginia Commonwealth University Enhancement of immune response
IT1255450B (it) * 1992-06-30 1995-10-31 Montefarmaco Spa Uso di acidi biliari come agenti antivirali
US5639866A (en) * 1993-02-23 1997-06-17 Princeton University Single-step formation of multiple glycosidic linkages
CA2156717C (en) * 1993-02-23 2001-05-29 Daniel E. Kahne Solution and solid-phase formation of glycosidic linkages
DE4316347C1 (de) * 1993-02-26 1994-08-18 Ina Dr Levi Verfahren zur Herstellung einer pharmazeutischen Zubereitung und Verwendung derselben zur Behandlung bestimmter Erkrankungen
US5846964A (en) * 1993-07-19 1998-12-08 Tokyo Tanabe Company Limited Hepatitis C virus proliferation inhibitor
KR100260110B1 (ko) * 1993-09-09 2000-07-01 라카일레 지. 필리페 담즙으로부터 추출된 면역조절제 조성물
US6551623B1 (en) 1993-09-09 2003-04-22 Lorus Therapeutics Inc. Immunomodulating compositions from bile
US5658560A (en) * 1994-01-18 1997-08-19 Serikov; Vladimir B. Method of treating endotoxemia by administering tyloxapol
US5646316A (en) * 1994-04-08 1997-07-08 Osteoarthritis Sciences, Inc. Bile acid inhibitors of metalloproteinase enzymes
WO1996028175A1 (en) 1995-03-16 1996-09-19 Imutec Pharma Inc. Immunomodulating compositions from bile for the treatment of immune system disorders
IT1282943B1 (it) * 1995-12-27 1998-04-02 Sanofi Winthrop S P A Composizione farmaceutica iniettabile__a base di acido ursodesossicoli co o tauroursodesossicolico
DE19631122A1 (de) * 1996-08-01 1998-02-05 Falk Pharma Gmbh Verwendung von Ursodeoxycholsäure bei HIV-Infektion
US7169889B1 (en) * 1999-06-19 2007-01-30 Biocon Limited Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
EP1333847A1 (de) * 2000-11-08 2003-08-13 Lorus Therapeutics Inc. Kombinationpräparate enthltend biologische verhaltensändernde stoffe und krebsmittel und ihre verwendung
KR20030005204A (ko) * 2000-12-25 2003-01-17 가부시키가이샤 시세이도 교감신경 활성화 향료 조성물
US7060675B2 (en) 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US6867183B2 (en) 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7713932B2 (en) 2001-06-04 2010-05-11 Biocon Limited Calcitonin drug-oligomer conjugates, and uses thereof
US6828305B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6713452B2 (en) * 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6835802B2 (en) * 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US6858580B2 (en) * 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828297B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US20040198819A1 (en) * 2001-06-20 2004-10-07 Young Aiping H. Biological response modifier composition and uses thereof
US7053076B2 (en) 2001-08-29 2006-05-30 Xenoport, Inc. Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs
US6770625B2 (en) * 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
US7030082B2 (en) * 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
US7312192B2 (en) * 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7166571B2 (en) * 2001-09-07 2007-01-23 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US6913903B2 (en) * 2001-09-07 2005-07-05 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7196059B2 (en) 2001-09-07 2007-03-27 Biocon Limited Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7601688B2 (en) * 2002-06-13 2009-10-13 Biocon Limited Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
MX2007000883A (es) * 2004-07-19 2007-04-02 Biocon Ltd Conjugados de insulina-oligomero, formulaciones y usos de los mismos.
BRPI0818004B8 (pt) 2007-10-16 2021-05-25 Biocon Ltd composição farmacêutica sólida administrável por via oral e o processo da mesma.
CN103570790B (zh) * 2012-08-07 2016-06-01 中国科学院上海药物研究所 原人参二醇衍生物及其制备方法、包含该衍生物的组合物及其用途
US11072630B2 (en) 2015-03-10 2021-07-27 Metselex, Inc. Fluorinated and alkylated bile acids
EP3968785A4 (de) 2019-05-14 2023-01-11 Tyme, Inc. Zusammensetzungen und verfahren zur behandlung von krebs
US10905698B1 (en) * 2020-05-14 2021-02-02 Tyme, Inc. Methods of treating SARS-COV-2 infections
WO2021231931A1 (en) * 2020-05-14 2021-11-18 Tyme, Inc. Methods of treating sars-cov-2 infections

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE44263B1 (en) * 1975-12-03 1981-09-23 Leo Pharm Prod Ltd New fusidic acid derivatives
GB8417895D0 (en) * 1984-07-13 1984-08-15 Marples B A Pharmaceutical anti-fungal composition

Also Published As

Publication number Publication date
GB8706313D0 (en) 1987-04-23
DK143088A (da) 1988-09-18
AU619174B2 (en) 1992-01-23
DE3889964D1 (de) 1994-07-14
EP0285285A3 (en) 1990-12-05
EP0285285A2 (de) 1988-10-05
DK143088D0 (da) 1988-03-16
AU1321688A (en) 1988-09-15
CA1317224C (en) 1993-05-04
US4957910A (en) 1990-09-18
EP0285285B1 (de) 1994-06-08
JPS63301823A (ja) 1988-12-08
ZA881856B (en) 1989-04-26
DE3889964T2 (de) 1994-09-15

Similar Documents

Publication Publication Date Title
ATE106729T1 (de) Verfahren und zusammensetzung zur behandlung und vorbeugung von virus-infektionen.
ATE395922T1 (de) Lipid-analoge zur behandlung von viralen infektionen
DE59209735D1 (de) Durch Hitze und/oder Detergens virusinaktiviertes Blutprodukt
ATE122654T1 (de) Behandlung von hiv-infizierungen und nützliche verbindungen dafür.
HUT47855A (en) Process for production of medical compositions containing two-faded dns and applicable in loco
ATE85523T1 (de) Taurohyodeoxycholsaeure zur behandlung von gallenwegssteinen und gallenstoerungen.
DK538888A (da) Anvendelse af castanosperminestere til fremstilling af et farmaceutisk praeparat
ATE273011T1 (de) Zusammensetzung und verfahren zur behandlung von herpes simplex
ATE143804T1 (de) Zusammensetzung zur behandlung von mastitis und metritis
EE9400068A (et) Ravimsegud viirushepatiidi B (HBV) infektsiooni ja selle poolt p6hjustatud haiguste raviks ja nende valmistamise protsess
UA13377A (uk) Спосіб одержаhhя противірусhого засобу
DE69011870D1 (de) Verfahren und zubereitung für die behandlung von hiv-infizierten säugetieren.
ATE115863T1 (de) Verwendung eines immunglobulinhaltigen präparates zur prophylaxe und therapie von aids beim menschen.
DE69109314D1 (de) Humaner monoklonaler Antikörper und diesen enthaltende Arzneimittelzusammensetzung zur Behandlung von Pseudomonasinfektionen.
DE69010523D1 (de) Kit oder Zusammensetzung zur Vorbeugung oder Behandlung von HIV-1 Infektionen.
ATE88752T1 (de) Inaktivierung von human immunodeficiency virus (hiv) in proteinhaltigen loesungen durch phenole.
ATE28563T1 (de) Podophyllotoxin-zubereitungen fuer behandlung von genitalwarzen.
ATE335494T1 (de) Verwendung von n-glycolneuraminsäure und deren derivaten zur herstellung eines medikaments zur behandlung von hiv-infektionen
SU1263246A1 (ru) Способ лечени острого стоматита
DE3883754D1 (de) Mittel zur prophylaxe und behandlung von viralen infektionskrankheiten.
ATE137968T1 (de) Verwendung von l-2-oxothiazolidine-4-carboxylate zur herstellung eines arzneimittels zur behandlung von latenten hiv-infektionen
ATE56878T1 (de) Verfahren und zusammensetzung zur vorbeugung und behandlung von virus-infektionen.
DE69006187D1 (de) Verwendung von Chinolyl- und Isochinolyloxazol-2-onen zur Herstellung eines Arzneimittels zur Verhinderung der Ansteckungsfähigkeit von mit Glykoproteinen umhüllten Viren.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee